 |
 |
|
|
 |
|
| Company Name |
D. Western Therapeutics Institute, Inc. |
| Business Field |
Discovery and Development of new drugs |
| Establishment |
February 26, 1999 |
| Capital Fund |
1,279million yen (as of 30th Jun. 2010) |
| Head office |
1-18-11, Nishiki, Naka-ku, Nagoya-shi, Aichi 460-0003, Japan |
| R&D Laboratory |
Institute of Human Research Promotion and Drug Development,Mie University Faculty of Medicine,Room 432, University Research Hall ,Mie University,2-174, Edobashi, Tsu shi, Mie 514-8507, Japan |
| President and CEO |
Yuichi Hidaka |
| Executive Director, CSO, General Manager, Research & Development Laboratory |
Hiroyoshi Hidaka |
| Executive Director, General Manager, R&D Planning Division |
Akiyosi Kawai |
| Executive Director, General Manager, General Administration Division |
Nobutsuna Tachibana |
| Director |
Masakatsu Nishikawa |
| Director |
Yoshiyuki Yamakawa |
| 1999.2 |
aimed to develop new drugs, established D. Western Therapeutics Institute, Inc. as a private company in Showa-ku Nagoya City. |
| 2001.3 |
agreed for exclusive license of development, production, and sales for anti-cancer drug (HMN-214) with Nippon Shinyaku Co., Ltd. |
| 2002.9 |
contracted for development and implementation of anti-platelet drug (K-134) and anti-glaucoma drug (K-115) with Kowa Co., Ltd. |
| 2004.7 |
initiated phase I trial for anti-platelet drug (K-134) in Europe. |
| 2004.10 |
completed phase I trial for anticancer drug (HMN-214) in U.S. |
| 2004.11 |
converted to a joint-stock corporation. |
| 2005.4 |
completed phase I trial for anti-platelet drug (K-134) in Europe. |
| 2005.12 |
moved head office to Naka-ku Nagoya City. |
| 2006.4 |
initiated phase I trial for anti-platelet drug (K-134) in Japan. |
| 2006.7 |
initiated phase I trial for anti-glaucoma drug (K-115) in Japan. successfully identified molecular target protein of anti-platelet drug (K-134) |
| 2006.12 |
established Institute of Human Research Promotion and Drug Development at Mie University Faculty of Medicine under collaborative research agreement. |
| 2007.10 |
completed phase I trial for anti-platelet drug (K-134) in Japan.
completed phase I trial for anti-glaucoma drug (K-115) in Japan. |
| 2008.4 |
Contracted collaborative research agreement with RIKEN (Independent Administrative Institution) for probe study in Positron Emission Tomography. |
| 2008.7 |
initiated phase II trial for anti-platelet drug (K-134) in Japan. |
| 2008.12 |
initiated phase II trial for anti-platelet drug (K-134) in U.S. |
| 2009.3 |
initiated phase II trial for anti-glaucoma drug (K-115) in Japan. |
| 2009.10 |
Listed on Osaka Stock Exchange JASDAQ. |
|
|
|
| | | | |
| |
|
 |
